Iconovo publishes outcome of exercise of warrants series TO 1
On 16 March 2026, the subscription period for exercise of warrants series TO 1 ("TO 1") for subscription of shares in Iconovo AB (publ) ("Iconovo"…
Iconovo’s rights issue is registered – conversion of BTA into shares
Iconovo AB (publ) (“Iconovo” or the “Company”) has carried out a rights issue of shares with pre-emption rights for existing shareholders that was completed on 27 February 2026 (the “Rights Issue”). The Rights Issue has today been registered with the Swedish Companies Registration Office and the last day of trading in paid subscribed shares (“BTA”) is on 12 March 2026. The record date is 16 March 2026, after which the BTAs will be converted into shares as of 18 March 2026.
Iconovo announces final outcome in the rights issue
Iconovo AB (publ) (”Iconovo” or the “Company”) today announces the final outcome of the rights issue of shares, which was announced on 25 November 2025 (the “Rights Issue"). The final outcome shows that the Rights Issue has been subscribed to a total of approximately 97.43 percent, of which approximately 87.19 percent were subscribed with subscription rights, approximately 10.24 percent were subscribed without subscription rights. Accordingly, 549,600 shares, corresponding to approximately 2.57 percent of the Rights Issue, will be allotted to the guarantors, whereby the Rights Issue has been subscribed to a total of approximately 100 percent. Iconovo thus receives approximately MSEK 24.6 before issuing costs.
Iconovo publishes preliminary outcome of rights issue and announces recalculation of warrants series TO 1
Iconovo AB (publ) (“Iconovo” or the “Company”) today announces the preliminary outcome of the rights issue of shares, which was announced on 25 November 2025 (the “Rights Issue”). The preliminary outcome indicates that the Rights Issue has been subscribed to a total of approximately 97.43 percent, of which approximately 87.19 percent were subscribed with subscription rights, and approximately 10.24 percent were subscribed without subscription rights. Based on the preliminary outcome, guarantee commitments will be utilized with an amount of approximately MSEK 0.6. Based on the preliminary outcome, Iconovo will receive approximately MSEK 24.6 before issuing costs through the Rights Issue. The Company can also announce that after completion of the recalculation, the number of shares that each warrant series TO 1 ("TO1") entitles to subscription for and the subscription price per share will remain unchanged.
Iconovo and Lonza signs LOI regarding strategic collaboration
Iconovo AB (publ.) today announces that it has signed a Letter of Intent (LOI) with Lonza with the aim of forging a lasting strategic collaboration in the area “spray dried formulation” capabilities, which is crucial to drug formulation of biologics suitable for inhalation.
The subscription period in Iconovo’s rights issue begins today
Today, on 13 February 2026, the subscription period begins for Iconovo AB’s (“Iconovo” or the “Company”) new issue of shares of approximately SEK 24.6 million with preferential rights for the Company’s existing shareholders, resolved by the Board of Directors on 25 November 2025 and approved by the Extraordinary General Meeting on 15 December 2025 (the “Rights Issue”). The subscription period for the Rights Issue runs until 27 February 2026. Please note, however, that certain banks and custodians may have an earlier deadline for subscription in the Rights Issue. Shareholders should therefore check with their bank or custodian to see if they have an earlier deadline for subscription.
Iconovo publishes information document regarding rights issue of shares
Iconovo AB ("Iconovo" or the "Company") publishes an information document (the "Information Document") relating to the rights issue of shares of approximately SEK 24.6 million before deduction of issue costs (the "Rights Issue"), which was resolved by the Board of Directors on 25 November 2025 and approved by the Extraordinary General Meeting on 15 December 2025.
Year-end report 1 January – 31 December 2025
SIGNIFICANT EVENTS DURING 1 OCTOBER – 31 DECEMBER 2025In mid-October, the company announced that it is withdrawing the financial targets communicated…
Iconovo has initiated a new feasibility study for ICOone® Nasal in collaboration with multinational company
Iconovo AB (publ.), a leader in the development of inhalable drugs based on proprietary inhalers and dry powder formulations, today announces that it has agreed to conduct a feasibility study on behalf of a large multinational company, to evaluate its preparation in ICOone® Nasal, Iconovo’s proprietary single-use nasal delivery platform.
EPO declares intention to approve ICOpre® patent application
Iconovo AB today announced that The European Patent Office (EPO) declares its intention to approve Iconovos patent application for the inhaler platform ICOpre® (Communication under Rule 71(3) EPC). The patent describes the proprietary design of dose-administering in Iconovos ICOpre® inhaler, which is deemed inter-changeable for GSKs Ellipta® inhaler. The patent is also pending approval in USA and China.
